27.09.2019 02:43:34
|
AbbVie Receives FDA Approval Of MAVYRET
(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved MAVYRET or glecaprevir/pibrentasvir to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C or HCV patients across all genotypes or GT1-6.
In August 2017, MAVYRET received regulatory approval in the U.S. as an 8-week, pan-genotypic treatment for treatment-naïve HCV patients without cirrhosis.
Glecaprevir was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Enanta Pharmaceuticals Incmehr Nachrichten
24.11.24 |
Ausblick: Enanta Pharmaceuticals mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
10.11.24 |
Erste Schätzungen: Enanta Pharmaceuticals legt Quartalsergebnis vor (finanzen.net) |
Analysen zu AbbVie Incmehr Analysen
Aktien in diesem Artikel
AbbVie Inc | 193,94 | -0,63% |
|
Enanta Pharmaceuticals Inc | 6,00 | -4,76% |
|